Workflow
Klotho Neurosciences, Inc.(KLTO)
icon
Search documents
Klotho Neurosciences, Inc.(KLTO) - 2023 Q4 - Annual Report
2024-04-17 01:54
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________ to ________________ Commission file number: 001-41340 REDWOODS ACQUISITION CORP. (Exact name of registrant as specified in its charter) | --- | --- | |--------- ...
Klotho Neurosciences, Inc.(KLTO) - 2023 Q3 - Quarterly Report
2023-11-17 02:31
Financial Performance - For the three months ended September 30, 2023, the company reported a net income of $290,145, compared to a net income of $731,121 for the same period in 2022[156]. - For the nine months ended September 30, 2023, the company had a net income of $1,257,210, an increase from $517,286 for the same period in 2022[157]. - The company generated non-operating income of $741,827 from interest earned on investments held in the Trust Account for Q3 2023[156]. - The company incurred franchise tax expenses of $33,000 for Q3 2023, compared to $39,300 in Q3 2022[156]. Business Combination and Acquisition Plans - The company plans to acquire ANEW Medical, Inc. for an implied equity value of $60,000,000, with additional contingent shares based on stock performance[147]. - The company extended the deadline to consummate a business combination from April 4, 2023, to December 4, 2024, with monthly extensions costing $35,000 each[145][146]. - The company expects to continue incurring significant costs in pursuit of its acquisition plans[140]. - The company has incurred significant professional costs to remain publicly traded and expects to continue incurring transaction costs related to the business combination[169]. Shareholder and Redemption Information - An aggregate of 3,636,456 shares with a redemption value of approximately $39,255,410 were tendered for redemption during the special meeting on November 13, 2023[145]. - A total of 6,103,350 shares were tendered for redemption at a total redemption amount of $63,169,451, averaging $10.35 per share[162]. - The company has issued multiple unsecured, non-interest bearing promissory notes to the Sponsor, totaling up to $1,260,000, which can be converted into shares upon business combination[171][172][174][175][176]. Financial Position and Assets - As of September 30, 2023, the Trust Account held marketable securities valued at $57,811,916, which are primarily invested in U.S. government securities[167]. - As of September 30, 2023, the company reported a working capital deficit of $755,526, excluding redemptions payable to public stockholders[168]. - As of September 30, 2023, the assets held in the Trust Account were primarily in cash and U.S. Treasury securities, with fair values determined using Level 1 measurements[183]. - The fair value of the Company's financial instruments approximates the carrying amounts on the consolidated balance sheet, with cash and cash equivalents estimated to approximate carrying values as of September 30, 2023[188]. IPO and Offering Costs - The company completed its IPO on April 4, 2022, raising gross proceeds of $100,000,000 from the sale of 10,000,000 Public Units at $10.00 each[158]. - An additional 1,500,000 Public Units were sold through the over-allotment option, generating gross proceeds of $15,000,000[159]. - The company incurred transaction costs of $8,365,339 related to the IPO, including $2,875,000 in underwriting fees and $4,312,500 in deferred underwriting fees[161]. - Offering costs related to the IPO were charged to stockholders' equity upon completion, allocated between public shares and public rights based on relative fair values[200]. Accounting and Internal Controls - The Company accounts for its Public Warrants as equity and Private Warrants as liabilities, with changes in estimated fair value recognized as non-cash gains or losses[196]. - Common stock subject to possible redemption is classified as temporary equity and presented at redemption value, with adjustments made to the carrying value as changes occur[197]. - The Company has conducted an evaluation of its disclosure controls and procedures as of September 30, 2023, concluding that they were effective during the reporting period[202]. - There has been no change in the internal control over financial reporting that materially affected the Company during the quarter ended September 30, 2023[203]. - The Company complies with FASB ASC 260 for net income (loss) per share calculations, allocating undistributed income (loss) between redeemable and non-redeemable shares[199]. Miscellaneous - The Company amended the conversion feature of its convertible promissory notes on May 15, 2023, resulting in a reclassification of these notes as debt at cash proceeds on the balance sheet[191]. - The Company granted Chardan a right of first refusal for future public and private equity offerings for a period of 18 months after the initial business combination[181]. - The company has no off-balance sheet arrangements as of September 30, 2023, and does not participate in transactions with unconsolidated entities[170].
Klotho Neurosciences, Inc.(KLTO) - 2023 Q2 - Quarterly Report
2023-08-21 21:27
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Units RWODU The Nasdaq Stock Market LLC Common Stock RWOD The Nasdaq Stock Market LLC Warrants RWODW The Nasdaq Stock Market LLC Rights RWODR The Nasdaq Stock Market LLC FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 ...
Klotho Neurosciences, Inc.(KLTO) - 2023 Q1 - Quarterly Report
2023-05-24 20:45
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Units RWODU The Nasdaq Stock Market LLC Common Stock RWOD The Nasdaq Stock Market LLC Warrants RWODW The Nasdaq Stock Market LLC Rights RWODR The Nasdaq Stock Market LLC FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 1 ...
Klotho Neurosciences, Inc.(KLTO) - 2022 Q4 - Annual Report
2023-04-10 21:00
Financial Performance - For the year ended December 31, 2022, the company reported a net income of $1,233,352, which included interest earned of $1,656,478 and a change in fair value of warrant liabilities of $555,917[61]. - The company had cash of $340,962 and working capital of $299,788 as of December 31, 2022, excluding income tax and franchise tax payable[68]. IPO Details - The company completed its IPO on April 4, 2022, raising gross proceeds of $100,000,000 from the sale of 10,000,000 Public Units at $10.00 each[62]. - An additional 1,500,000 Public Units were sold through an over-allotment option, generating gross proceeds of $15,000,000[63]. - The company incurred total transaction costs of $8,365,339 related to the IPO, including $2,875,000 in underwriting fees and $4,312,500 in deferred underwriting fees[66]. - Offering costs related to the IPO were charged to stockholders' equity upon completion, allocated based on the relative fair values of public shares, warrants, and rights[86]. Trust Account and Business Combination - As of December 31, 2022, the Trust Account held marketable securities valued at $117,806,478, consisting of U.S. government securities[67]. - The company plans to utilize funds from the Trust Account primarily for acquiring a target business and covering related expenses[67]. - The company has until April 4, 2023, to complete a Business Combination, or it will face mandatory liquidation[69]. Debt and Financial Obligations - The company has no long-term debt or capital lease obligations as of the reporting date[71]. - The company is subject to a 1% excise tax on stock repurchases after December 31, 2022, which may affect the attractiveness of business combinations[92]. Regulatory and Compliance Matters - The company is considered a "foreign person" under CFIUS regulations, which may limit potential business combination opportunities and require mandatory filings[93]. - The company evaluated its disclosure controls and procedures as effective as of December 31, 2022[101]. - The company does not expect its disclosure controls and procedures to prevent all errors and instances of fraud, providing only reasonable assurance[102]. - There were no changes in internal control over financial reporting during the most recent fiscal quarter that materially affected the company's internal controls[103]. Accounting and Reporting - The company accounts for public warrants as equity and private warrants as liabilities, with the assessment conducted at issuance and quarterly thereafter[82][83]. - Common stock subject to possible redemption is classified as temporary equity and presented at redemption value, with adjustments recognized immediately[84]. - The company reported compliance with FASB ASC 260 for net income (loss) per share, allocating undistributed income based on the weighted average number of shares outstanding[85]. - As an emerging growth company, the company is allowed to delay the adoption of new accounting standards, which may affect comparability with non-emerging growth companies[98][99]. Administrative Agreements - The company has entered into an administrative services agreement to pay the Sponsor $10,000 per month for support services[73]. Off-Balance Sheet Arrangements - The company has no off-balance sheet arrangements as of December 31, 2022[97].
Klotho Neurosciences, Inc.(KLTO) - 2022 Q3 - Quarterly Report
2022-11-14 22:18
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 New York, NY 10010 (Address of principal executive offices) For the transition period from to (Exact name of registrant as specified in its charter) (646) 916-5315 Delaware 86-2727441 ( ...
Klotho Neurosciences, Inc.(KLTO) - 2022 Q2 - Quarterly Report
2022-08-15 21:08
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-41340 Redwoods Acquisition Corp. (Exact name of registrant as specified in its charter) Delaware 86-2727441 (State or other juri ...
Klotho Neurosciences, Inc.(KLTO) - 2022 Q1 - Quarterly Report
2022-05-16 20:33
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-41340 Redwoods Acquisition Corp. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorpo ...